As a Free StocksGuide user, you can view scores for all 7,052 stocks worldwide.
12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
12 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 5,019 5,019 |
51%
51%
|
|
| Gross Profit | 4,316 4,316 |
56%
56%
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | 144 144 |
116%
116%
|
|
| Net Profit | -22 -22 |
98%
98%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
| Head office | Cayman Islands |
| CEO | John Oyler |
| Employees | 11,000 |
| Founded | 2010 |
| Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


